Strategic collaboration enables customers to harness the value of data capture coupled with data quality oversight
Fort Lauderdale, FL, October 20, 2015 - OmniComm Systems, Inc. (OmniComm) (OTCQX: OMCM), a global leading provider of clinical data management technology, today announced a partnership with CluePoints, a leading software provider of risk-based monitoring (RBM) solutions for clinical trials. Under the partnership, the two companies will work together to deliver OmniComm's electronic data capture (EDC) technology and services integrated with CluePoints' RBM software, offering customers a best-in-class solution that couples data collection with complete oversight of data quality.
Meeting the challenges of clinical data oversight in the age of more complex and global clinical trials is increasingly difficult for sponsors. OmniComm’s outcomes orientated EDC solutions enhance data quality while reducing query rates. By bringing its solutions together with CluePoints' Central Statistical Monitoring (CSM) solution, which supports robust statistically driven RBM and quality assurance strategies, the two companies can offer customers a sophisticated way of collectively embedding data capture, analysis and visualization into their processes in a single step.
Steve Young, senior director of transformation services at OmniComm, comments, "We are delighted to partner with CluePoints. As a provider of leading edge EDC and RBM enablement technology and services, integrating their powerful RBM software with TrialMaster® EDC technology and our RBM enablement services helps us advance the use of our systems outside the periscope of data capture. Together we can provide an answer to the challenging questions of clinical data oversight, streamlining processes and helping our customers to improve their outcomes."
CluePoints’ CEO, FranÒ«ois Torche, said, "Collectively our customers are looking to harness the value of EDC technology coupled with analytics for RBM and data quality oversight. The integration of our services and solutions will mean that they can get the best out of both systems, providing them with reassurance that they are achieving the highest quality data possible." CluePoints and OmniComm will together present 'The RBM Roadshow', a special thought leadership event discussing the benefits derived from an integrated solution for EDC technology, targeted source data verification (SDV), and centralized analytics/key risk indicators (KRIs). The events will take place in Cambridge, MA on November 4th, Chicago on November 9th and San Francisco on November 10th, 2015. To find out more and register, visit http://offers.omnicomm.com/rbm-roadshow-series.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.